PRECOS

United Kingdom Founded: 2010 • Age: 16 yrs Acquired By Crown Bioscience
Preclinical oncology services with xenograft and metastatic models are provided.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees 8 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About PRECOS

PRECOS is a company based in United Kingdom founded in 2010 was acquired by Crown Bioscience in July 2013. The company has 8 employees as of May 31, 2021. PRECOS operates in a competitive market with competitors including Orakl Oncology, Oncodesign, Orange Grove Bio LLC, Lytica Therapeutics and LumaBridge, among others.

  • Headquarter United Kingdom
  • Employees 8 as on 31 May, 2021
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Proweb (Uk) Limited
  • Date of Incorporation 21 Feb, 1996
  • Jurisdiction NOTTINGHAM
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    8

    as on May 31, 2021

  • Acquired by
    Crown Bioscience

    (Jul 30, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of PRECOS

Premium access

Detailed funding history for PRECOS

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in PRECOS

PRECOS has secured backing from 1 investor. Prominent investors backing the company include Crown Bioscience.

All
Investor Description Founded Year Domain Location
Cancer and CVMD drugs are developed using PDX models.
Locked Locked Locked
Premium access

Investor details for PRECOS

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by PRECOS

Investments
Premium access

Investment portfolio details for PRECOS

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - PRECOS

Premium access

Detailed financials for PRECOS

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Precos Comparisons

PRECOS Primary company
Description
Preclinical oncology services with xenograft and metastatic ...
Location
United Kingdom
Founded Year
2010
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
8
As of 2021
Premium access

Peer comparison for PRECOS

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of PRECOS

PRECOS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, Orange Grove Bio LLC, Lytica Therapeutics and LumaBridge, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
Locked Locked Locked
Preclinical assessment services for anti-cancer therapies are provided.
Locked Locked Locked
Provider of preclinical development services
Locked Locked Locked
Therapeutic drugs are developed for medical applications.
Locked Locked Locked
Provider of oncology clinical research, regulatory affairs, and data management services
Locked Locked Locked
Developer of immune assays for the diagnosis of cancer
Premium access

Detailed competitors of PRECOS

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Precos

Premium access

Complete news archive for PRECOS

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PRECOS

PRECOS was founded in 2010.

PRECOS is headquartered in United Kingdom.

As of May 31, 2021, the latest employee count at PRECOS is 8.

PRECOS was founded in 2010 in the United Kingdom, focusing on the oncology drug development sector. Preclinical services, including patient-derived xenograft, orthotopic, and metastatic modeling along with imaging, were delivered. Models that mirrored cancer progression stagessuch as pre-cancerous lesions, primary tumors, and metastasiswere employed to support research. Acquisition by Crown Bioscience occurred in 2013.

PRECOS's top competitors include Oncodesign, Orakl Oncology and Lytica Therapeutics.

PRECOS has 1 investor. Key investors include Crown Bioscience.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available